Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
4.800
+0.050 (1.05%)
At close: Aug 14, 2026, 4:00 PM EDT
4.752
-0.048 (-1.00%)
After-hours: Aug 14, 2026, 7:35 PM EDT

Relmada Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-62.23-56.2-83.89-103.7-161.25-125.7
Net Income
-61.93-57.39-79.98-98.79-157.04-125.75
Earnings Per Share
-0.85-1.45-2.65-3.28-5.30-7.16
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
217.7393.0144.9196.32148.32211.91
Total Debt
------
Net Cash (Debt)
217.7393.0144.9196.32148.32211.91
Net Cash Growth
955.95%107.10%-53.38%-35.06%-30.01%80.98%
Net Cash Per Share
2.972.361.493.205.0112.07

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-45.99-45.79-51.76-51.66-103.8-91.87
Capital Expenditures
------
Free Cash Flow
-45.99-45.79-51.76-51.66-103.8-91.87
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.